The Food and Drug Administration (FDA) has approved Xtoro (finafloxacin otic suspension; Alcon) for the treatment of acute otitis externa (also known as swimmer's ear) caused by Pseudomonas aeruginosa and Staphylococcus aureus.
Some people with cochlear implants experience pain, discomfort, and problems with the implant's internal magnet when they undergo magnetic resonance imaging (MRI).
Nearly one million patient visits are made to doctors offices, outpatient clinics, and emergency departments for keratitis each year in the United States, with contact lens wear as the single largest risk factor for microbial keratitis.
Featured courses from mycme
An understanding of the growing problem of allergic disease, how AD is the entryway into ...
This module reviews all topics on the NCCPA examination blueprint relating to Pulmonology, Ophthalmology, and ...
This activity covers the diagnosis and management of acute otitis externa and proposes a grading ...
- Over 50 FDA-Approved Meds Could Treat Ebola Infection
- Pharmacy Employees Arrested, Charged in Meningitis Outbreak
- How Effective Are Neuraminidase Inhibitors in Containing Flu?
- Ondansetron, Tramadol Drug Interaction Identified
- Pain Management in Patients with IBD: Individualizing Treatment Approaches